Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1979 Apr;42(4):338–344. doi: 10.1136/jnnp.42.4.338

Prolonged azathioprine treatment of non-remitting multiple sclerosis

J A Rosen 1,2
PMCID: PMC490204  PMID: 458481

Abstract

Two groups of 85 and 42 ambulatory patients with moderately advanced non-remitting multiple sclerosis were treated for six to 14 and three to six years with daily azathioprine. Less than 10% of these patients became confined to a wheelchair. This far exceeds any possible result in a group of non-remitting multiple sclerosis patients not so treated.

Full text

PDF
338

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ALLISON R. S. Survival in disseminated sclerosis: a clinical study of a series of cases first seen 20 years ago. Brain. 1950;73(1):103–120. doi: 10.1093/brain/73.1.103. [DOI] [PubMed] [Google Scholar]
  2. Adams C. W. The onset and progression of the lesion in multiple sclerosis. J Neurol Sci. 1975 Jun;25(2):165–182. doi: 10.1016/0022-510x(75)90138-0. [DOI] [PubMed] [Google Scholar]
  3. BAUER H. J., FIRNHABER W., WINKLER W. PROGNOSTIC CRITERIA IN MULTIPLE SCLEROSIS. Ann N Y Acad Sci. 1965 Mar 31;122:542–551. doi: 10.1111/j.1749-6632.1965.tb20234.x. [DOI] [PubMed] [Google Scholar]
  4. Drachman D. A., Paterson P. Y., Schmidt R. T., Spehlmann R. F. Cyclophosphamide in exacerbations of multiple sclerosis. Therapeutic trial and a strategy for pilot drug studies. J Neurol Neurosurg Psychiatry. 1975 Jun;38(6):592–597. doi: 10.1136/jnnp.38.6.592. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fog T., Jersild C., Dupont B., Platz P. J., Svejgaard A., Thomsen M., Midholm S., Raun N. E. Proceedings: Transfer factor treatment in multiple sclerosis. Neurology. 1975 May;25(5):489–490. [PubMed] [Google Scholar]
  6. Fog T. The course of multiple sclerosis. Acta Neurol Scand. 1966;42(5):608–611. doi: 10.1111/j.1600-0404.1966.tb01212.x. [DOI] [PubMed] [Google Scholar]
  7. HOYER L. W., GOOD R. A., CONDIE R. M. Experimental allergic encephalomyelitis: the effect of 6-mercaptopurine. J Exp Med. 1962 Sep 1;116:311–327. doi: 10.1084/jem.116.3.311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. HYLLESTED K. Lethality, duration, and mortality of disseminated sclerosis in Denmark. Acta Psychiatr Scand. 1961;36:553–564. doi: 10.1111/j.1600-0447.1961.tb01774.x. [DOI] [PubMed] [Google Scholar]
  9. Jersild C., Svejgaard A., Fog T. HL-A antigens and multiple sclerosis. Lancet. 1972 Jun 3;1(7762):1240–1241. doi: 10.1016/s0140-6736(72)90962-2. [DOI] [PubMed] [Google Scholar]
  10. Kurtzke J. F., Beebe G. W., Nagler B., Nefzger M. D., Auth T. L., Kurland L. T. Studies on the natural history of multiple sclerosis. V. Long-term survival in young men. Arch Neurol. 1970 Mar;22(3):215–225. doi: 10.1001/archneur.1970.00480210025003. [DOI] [PubMed] [Google Scholar]
  11. LAZARTE J. A. Multiple sclerosis: prognosis for ambulatory and nonambulatory patients. Res Publ Assoc Res Nerv Ment Dis. 1950;28:512–523. [PubMed] [Google Scholar]
  12. LEIBOWITZ U., ALTER M., HALPERN L. CLINICAL STUDIES OF MULTIPLE SCLEROSIS IN ISRAEL. 3. CLINICAL COURSE AND PROGNOSIS RELATED TO AGE AT ONSET. Neurology. 1964 Oct;14:926–932. doi: 10.1212/wnl.14.10.926. [DOI] [PubMed] [Google Scholar]
  13. Lance E. M., Kremer M., Abbosh J., Jones V. E., Knight S., Medawar P. B. Intensive immunosuppression in patients with disseminated sclerosis. I. Clinical response. Clin Exp Immunol. 1975 Jul;21(1):1–12. [PMC free article] [PubMed] [Google Scholar]
  14. Lisak R. P. Multiple sclerosis: immunologic aspects. Ann Clin Lab Sci. 1975 Sep-Oct;5(5):324–329. [PubMed] [Google Scholar]
  15. MCALPINE D. The benign form of multiple sclerosis. A study based on 241 cases seen within three years of onset and followed up until the tenth year or more of the disease. Brain. 1961 Jun;84:186–203. doi: 10.1093/brain/84.2.186. [DOI] [PubMed] [Google Scholar]
  16. MULLER R. Course and prognosis of disseminated sclerosis in relation to age of onset. AMA Arch Neurol Psychiatry. 1951 Nov;66(5):561–570. [PubMed] [Google Scholar]
  17. MacLEAN A. R., BERKSON J. Mortality and disability in multiple sclerosis; a statistical estimate of prognosis. J Am Med Assoc. 1951 Aug 11;146(15):1367–1369. doi: 10.1001/jama.1951.03670150001001. [DOI] [PubMed] [Google Scholar]
  18. McALPINE D., COMPSTON N. Some aspects of the natural history of disseminated sclerosis. Q J Med. 1952 Apr;21(82):135–167. [PubMed] [Google Scholar]
  19. Miyamoto H., Walker J. E., Ginsberg A. H., Burks J. S., McIntosh K., Kempe C. H. Antibodies to vaccinia and measles viruses in multiple sclerosis patients. Arch Neurol. 1976 Jun;33(6):414–417. doi: 10.1001/archneur.1976.00500060020005. [DOI] [PubMed] [Google Scholar]
  20. Paterson P. Y., Drobish D. G. Cyclophosphamide: effect on experimental allergic encephalomyelitis in Lewis rats. Science. 1969 Jul 11;165(3889):191–192. doi: 10.1126/science.165.3889.191. [DOI] [PubMed] [Google Scholar]
  21. SCHUMACHER G. A., BEEBE G., KIBLER R. F., KURLAND L. T., KURTZKE J. F., MCDOWELL F., NAGLER B., SIBLEY W. A., TOURTELLOTTE W. W., WILLMON T. L. PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS. Ann N Y Acad Sci. 1965 Mar 31;122:552–568. doi: 10.1111/j.1749-6632.1965.tb20235.x. [DOI] [PubMed] [Google Scholar]
  22. Salaman J. R., Millar D. Letter: Linoleic acid as an immunosuppressive agent. Lancet. 1975 Apr 12;1(7911):857–857. doi: 10.1016/s0140-6736(75)93030-5. [DOI] [PubMed] [Google Scholar]
  23. Schuller E., Delasnerie N., Deloche G., Loridan M. Multiple sclerosis: a two-phase disease? Acta Neurol Scand. 1973;49(4):453–460. doi: 10.1111/j.1600-0404.1973.tb01318.x. [DOI] [PubMed] [Google Scholar]
  24. Silberberg D., Lisak R., Zweiman B. Multiple sclerosis unaffected by azathioprine in pilot study. Arch Neurol. 1973 Mar;28(3):210–212. doi: 10.1001/archneur.1973.00490210090017. [DOI] [PubMed] [Google Scholar]
  25. Swinburn W. R., Liversedge L. A. Long-term treatment of multiple sclerosis with azathioprine. J Neurol Neurosurg Psychiatry. 1973 Feb;36(1):124–126. doi: 10.1136/jnnp.36.1.124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Vogel C. L., Calabresi P. Enhanced suppression of experimental allergic encephalomyelitis by combination chemotherapy with duazomycin-A and 6-mercaptopurine. Proc Soc Exp Biol Med. 1969 May;131(1):251–256. doi: 10.3181/00379727-131-33852. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES